{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:26:56Z","timestamp":1754152016077,"version":"3.41.2"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/igc.0b013e3182866944","type":"journal-article","created":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T04:13:40Z","timestamp":1359519220000},"page":"475-480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Weekly Topotecan for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma"],"prefix":"10.1016","volume":"23","author":[{"given":"Tamar","family":"Safra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Berman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adelya","family":"Yachnin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Bruchim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihai","family":"Meirovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frida","family":"Barak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Atlas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tally","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ora Solange","family":"Rosengarten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e3182866944_bb0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/978-1-60327-492-0_20","article-title":"Epidemiology of ovarian cancer","volume":"472","author":"Permuth-Wey","year":"2009","journal-title":"Methods Mol Biol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2009.11.033","article-title":"Achievements and unmet needs in the management of advanced ovarian cancer","volume":"117","author":"Guarneri","year":"2010","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000086967","article-title":"Current concepts of treatment strategies in advanced or recurrent ovarian cancer","volume":"68","author":"Salzberg","year":"2005","journal-title":"Oncology."},{"key":"10.1097\/IGC.0b013e3182866944_bb0020","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.2000.18.5.1062","article-title":"Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study","volume":"18","author":"McGuire","year":"2000","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0030","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1021\/bi00437a018","article-title":"On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex","volume":"28","author":"Hertzberg","year":"1989","journal-title":"Biochemistry."},{"key":"10.1097\/IGC.0b013e3182866944_bb0035","first-page":"5077","article-title":"Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin","volume":"49","author":"Hsiang","year":"1989","journal-title":"Cancer Res."},{"key":"10.1097\/IGC.0b013e3182866944_bb0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s002800050997","article-title":"Antiangiogenic potential of camptothecin and topotecan","volume":"44","author":"Clements","year":"1999","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0045","first-page":"181","article-title":"Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model","volume":"5","author":"O\u2019Leary","year":"1999","journal-title":"Clin Cancer Res."},{"key":"10.1097\/IGC.0b013e3182866944_bb0050","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","article-title":"Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study","volume":"14","author":"Creemers","year":"1996","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0055","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.1996.14.5.1552","article-title":"Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma","volume":"14","author":"Kudelka","year":"1996","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0060","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel-Huinink","year":"1997","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0065","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.1998.16.6.2233","article-title":"Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study","volume":"16","author":"Hoskins","year":"1998","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0070","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0075","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ygyno.2008.02.028","article-title":"Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers","volume":"109","author":"Morris","year":"2008","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/gyno.2000.5995","article-title":"Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel","volume":"80","author":"Bolis","year":"2001","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0085","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2009.27.8911","article-title":"Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"29","author":"Sehouli","year":"2011","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygyno.2006.11.017","article-title":"Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer","volume":"105","author":"Safra","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0095","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2007.08.062","article-title":"Weekly topotecan for recurrent platinum resistant ovarian cancer","volume":"108","author":"Abushahin","year":"2008","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0105","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ygyno.2004.08.026","article-title":"Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer","volume":"95","author":"Bhoola","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0110","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ygyno.2005.04.032","article-title":"Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma","volume":"98","author":"O\u2019Malley","year":"2005","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0115","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ygyno.2010.11.008","article-title":"A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q)","volume":"120","author":"Herzog","year":"2011","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0120","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182866944_bb0125","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2011.07.019","article-title":"Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers","volume":"123","author":"Hyman","year":"2011","journal-title":"Gynecol Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24018954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24018954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1097\/IGC.0b013e3182866944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:36:07Z","timestamp":1753101367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24018954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1048891X24018954"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e3182866944","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Weekly Topotecan for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e3182866944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2013 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}